Integra Lifesciences Holdings (Integra Lifesciences Holdings) Sloan Ratio % : 0.58% (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Integra Lifesciences Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Integra Lifesciences Holdings's Sloan Ratio for the quarter that ended in Dec. 2023 was 0.58%.

As of Dec. 2023, Integra Lifesciences Holdings has a Sloan Ratio of 0.58%, indicating the company is in the safe zone and there is no funny business with accruals.

Integra Lifesciences Holdings Sloan Ratio % Historical Data

The historical data trend for Integra Lifesciences Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Integra Lifesciences Holdings Sloan Ratio % Chart

Integra Lifesciences Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Sloan Ratio %

Get a 7-Day Free Trial

-0.56

-0.05

0.48

-0.65

0.58

Integra Lifesciences Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Sloan Ratio %	Get a 7-Day Free Trial															-0.65	-0.43	-0.20	0.70	0.58

Competitive Comparison of Integra Lifesciences Holdings's Sloan Ratio %

For the Medical Devices subindustry, Integra Lifesciences Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integra Lifesciences Holdings's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Sloan Ratio % falls into.

Integra Lifesciences Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Integra Lifesciences Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(67.741	-	139.955
	-	-94.178)	/	3781.988
	=	0.58%

Integra Lifesciences Holdings's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Dec. 2023 )
	=	(67.741	-	139.955
	-	-94.178)	/	3781.988
	=	0.58%

Integra Lifesciences Holdings's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was 24.226 (Mar. 2023 ) + 4.184 (Jun. 2023 ) + 19.497 (Sep. 2023 ) + 19.834 (Dec. 2023 ) = $68 Mil.
Integra Lifesciences Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was 26.156 (Mar. 2023 ) + 28.279 (Jun. 2023 ) + 26.77 (Sep. 2023 ) + 58.75 (Dec. 2023 ) = $140 Mil.
Integra Lifesciences Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -13.704 (Mar. 2023 ) + -15.548 (Jun. 2023 ) + -7.697 (Sep. 2023 ) + -57.229 (Dec. 2023 ) = $-94 Mil.

Integra Lifesciences Holdings (NAS:IART) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, Integra Lifesciences Holdings has a Sloan Ratio of 0.58%, indicating the company is in the safe zone and there is no funny business with accruals.

Integra Lifesciences Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Integra Lifesciences Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Integra Lifesciences Holdings (Integra Lifesciences Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Integra Lifesciences Holdings Corp (NAS:IART) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

IL3:Germany

Address

1100 Campus Road, Princeton, NJ, USA, 08540

Website

https://www.integralife.com

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman specialty surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Executives

Chantal Veillon-berteloot	officer: EVP & CHRO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Jeffrey Mosebrook	officer: SVP, Fin & PAO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Lea Daniels Knight	officer: EVP & CFO	1100 CAMPUS ROAD, PRINCETON NJ 08540
Eric Schwartz	officer: Corp VP, Gen Counsel & Sec	C/O ERESEARCHTECHNOLOGY, INC., 1818 MARKET STREET, SUITE 1000, PHILADELPHIA PA 19103
Witte Jan De	director, officer: President & CEO	C/O RESMED INC., 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA 92123
Michael J. Mcbreen	officer: Executive VP & President, CSS	1100 CAMPUS ROAD, PRINCETON NJ 08540
Harvinder Singh	officer: Exec VP & PRES, International	1100 CAMPUS ROAD, PRINCETON NJ 08540
Lisa Evoli	officer: Chief Human Resources Officer	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Raymond G. Murphy	director	14604 CARROLTON ROAD, ROCKVILLE MD 20853
Renee Wonlai Lo	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Glenn Coleman	officer: CVP, CHIEF FINANCIAL OFFICER	C/O DENTSLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Tru St Partnership, L.p.	10 percent owner	795 EAST LANCASTER AVE., STE. 200, VILLANOVA PA 19085
Peter J Arduini	officer: President & COO	311 ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Shaundra Clay	director	1100 CAMPUS ROAD, PRINCETON NJ 08540
Stuart Essig	director, officer: President and CEO	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536